上海医药(02607.HK)：注射用头孢唑林钠通过仿制药一致性评价

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium has received approval from the National Medical Products Administration [1] - The approval notice includes notification numbers 2026B01286 and 2026B01287 [1] - The drug has successfully passed the consistency evaluation of quality and efficacy for generic drugs [1]